Member Info for myepic

Have I missed some bad news ? generally good broker forecasts clinical trials re starting for head and neck But still falling sp ? Maybe if someone came along with a bit over 50 quid a share they could buy the company and save me a lot of head scratching?! :-)

Well like everybody else I wish I'd known this was happening a few hours earlier , I could of skipped out and in again ,but in the bigger picture, I think that they have found support at close to 320 demonstrates the robustness of this share/company , I guess the fact I bought in at 212 on june 24 when everybody was throwing themselves off a cliff makes it easier to be relaxed about it :-)

Hi Daisan I hope you are right , the numbers are definitely good , I Hold a bit of gold in a physical backer etf , more as a "if it all goes of the tracks rapidly" kind of balancer rather than really trading in or out ,so I am reading all the conflicting gold predictions, I may well be a bit over sensitive to Geopolitical risk as I was also invested in Oxus Gold ,that did not end well, despite my slight nervousness I remain invested in AAZ - I'm right back up to only 30% down now so I think I'll hold on for a pay cheque

Hi Daisan , I hope I am wrong about the geopolitical risk and Trump as President , I guess the best indicator would be to ask residents of Azerbaijan whether they now feel more or less comfortable about Russia looking at old USSR maps...

POG up but geopolitical risk up ................where have the Orange one and Vladimir agreed for that line to be drawn ?

From Seeking Alpha AstraZeneca has agreed to sell its small-molecule antibiotics operations to Pfizer (NYSE:PFE) in a transaction that could eventually be worth $1.575B. The deal will allow AstraZeneca (AZN -0.15% premarket) to focus on three main therapy areas and realize value "from the strong portfolio of established and late-stage small molecule antibiotics." Pfizer will pay $550M upfront plus $175M in January 2019, and as much as $850M in milestones and sales-related payments.

From IC Pharma giant AstraZeneca (AZN) has agreed to sell its late-stage antibiotics business to acquisition hungry Pfizer. The US group will pay Astra up to $1.5bn for its portfolio which consists of three already approved antibiotics and two currently undergoing clinical trials. According to management at Astra this will allow the group to focus more on its three main therapy areas, while allowing Pfizer - a world leader in infectious diseases - to bring its antibiotics to market effectively. The deal is not expected to impact current year forecasts and we still rate Astra a buy.